Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Royalty Pharma ( (RPRX) ).
On August 13, 2025, Henry Fernandez stepped down from his role as Lead Independent Director of Royalty Pharma‘s Board of Directors. Fernandez, who joined the board in July 2020 and was appointed Lead Independent Director in March 2021, has been credited with helping the company achieve significant milestones and positioning it for future growth. His departure was not due to any disagreements with the company, and the board expressed gratitude for his contributions. Royalty Pharma plans to appoint a new Lead Independent Director soon.
The most recent analyst rating on (RPRX) stock is a Buy with a $42.00 price target. To see the full list of analyst forecasts on Royalty Pharma stock, see the RPRX Stock Forecast page.
Spark’s Take on RPRX Stock
According to Spark, TipRanks’ AI Analyst, RPRX is a Outperform.
Royalty Pharma’s strong operational efficiency and positive earnings call are the most significant factors driving the score. The stock’s technical indicators show positive momentum, and its valuation is reasonable. Corporate governance improvements further support the stock’s outlook. However, challenges in profitability and a royalty dispute with Vertex present risks.
To see Spark’s full report on RPRX stock, click here.
More about Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry. The company collaborates with a range of innovators, from academic institutions and research hospitals to small and mid-cap biotechnology companies and leading global pharmaceutical companies. Royalty Pharma’s portfolio includes royalties on more than 35 commercial products, and it funds innovation both directly and indirectly through partnerships and acquisitions.
Average Trading Volume: 4,238,497
Technical Sentiment Signal: Buy
Current Market Cap: $20.52B
Find detailed analytics on RPRX stock on TipRanks’ Stock Analysis page.